Wang Minhui, Zhou Jiaxin, Zhan Feng, Luo Hui, Duan Xinwang, Zhao Cheng, Wu Zhenbiao, Li Hongbin, Yang Min, Li Qin, Xu Jian, Huang Can, Zhao Jiuliang, Wang Qian, Leng Xiaomei, Tian Xinping, Zhao Yan, Zeng Xiaofeng, Cao Heng, Li Mengtao
Department of Rheumatology and Clinical ImmunologyMinistry of Science & Technology, State Key Laboratory of Complex Severe and Rare DiseasesKey Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Chinese Academy of Medical Sciences & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Peking Union Medical College Hospital (PUMCH), Shuaifuyuan No. 1, Dongcheng District, Beijing, China.
Department of Rheumatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Clin Rheumatol. 2025 May 16. doi: 10.1007/s10067-025-07476-y.
Patients with systemic lupus erythematosus (SLE) are at high risk of cardiovascular disease (CVD), fragility fractures, and malignancies. However, data regarding these comorbidities among Chinese SLE patients are limited. We aimed to determine the prevalence of and risk factors for these three major comorbidities in a large cohort of Chinese SLE patients.
In this cross-sectional study, demographic, clinical, and common comorbidity profiles were obtained from the medical records of SLE patients enrolled in the Chinese SLE Treatment and Research group (CSTAR) registry. Univariate and multivariate logistic regression analyses were performed to identify possible risk factors related to these comorbidities.
A total of 38,105 SLE patients were included (92.2% women). The median age at registration was 34.0 years (interquartile range, 27.0-46.0 years). The prevalence rates of the three important comorbidities at baseline were as follows: CVD, 1.9% (95% confidence interval [CI]: 1.8-2.0%); fragility fractures, 0.7% (95% CI: 0.6-0.8%); and malignancies, 0.7% (95% CI: 0.6-0.8%). In the multivariable-adjusted model, lupus anticoagulant, anticardiolipin antibody, anti-β2GP1 antibody, neuropsychiatric involvement, and hematological involvement were positively associated with CVD in SLE patients. Mucocutaneous manifestations, hyperimmunoglobulinemia, hypocomplementemia, anti-dsDNA, anti-Sm, and anti-nRNP/U1RNP antibody, and hydroxychloroquine therapy were negatively associated with CVD. The multivariate analysis revealed that age older than 50 years and hypocomplementemia were associated with fragility fractures and malignancies.
CVD, fragility fractures, and malignancies commonly occur in SLE patients. Patients with traditional and SLE-related factors should be more carefully monitored for these important comorbidities. Key Points • SLE patients have an increased risk of cardiovascular disease, fragility fractures, and malignancy. However, data regarding these comorbidities among Chinese SLE patients are limited. • Several associated risk factors for these three comorbidities of SLE were identified.Characteristics, symptom severity, and QOL differ in different age groups. • Lupus patients with traditional and SLE-related factors should be more carefully monitored for the presence of these comorbidities.
系统性红斑狼疮(SLE)患者患心血管疾病(CVD)、脆性骨折和恶性肿瘤的风险较高。然而,关于中国SLE患者中这些合并症的数据有限。我们旨在确定一大群中国SLE患者中这三种主要合并症的患病率及危险因素。
在这项横断面研究中,从中国SLE治疗与研究组(CSTAR)登记处登记的SLE患者的病历中获取人口统计学、临床和常见合并症资料。进行单因素和多因素逻辑回归分析以确定与这些合并症相关的可能危险因素。
共纳入38105例SLE患者(92.2%为女性)。登记时的中位年龄为34.0岁(四分位间距,27.0 - 46.0岁)。基线时三种重要合并症的患病率如下:CVD,1.9%(95%置信区间[CI]:1.8 - 2.0%);脆性骨折,0.7%(95%CI:0.6 - 0.8%);恶性肿瘤,0.7%(95%CI:0.6 - 0.8%)。在多变量调整模型中,狼疮抗凝物、抗心磷脂抗体、抗β2糖蛋白1抗体、神经精神受累和血液学受累与SLE患者的CVD呈正相关。皮肤黏膜表现、高免疫球蛋白血症、低补体血症、抗双链DNA抗体、抗Sm抗体、抗nRNP/U1RNP抗体和羟氯喹治疗与CVD呈负相关。多因素分析显示,年龄大于50岁和低补体血症与脆性骨折和恶性肿瘤相关。
CVD、脆性骨折和恶性肿瘤在SLE患者中常见。对于有传统因素和SLE相关因素的患者,应更仔细地监测这些重要合并症。要点 • SLE患者患心血管疾病、脆性骨折和恶性肿瘤的风险增加。然而,关于中国SLE患者中这些合并症的数据有限。 • 确定了SLE这三种合并症的几个相关危险因素。不同年龄组的特征、症状严重程度和生活质量有所不同。 • 对于有传统因素和SLE相关因素的狼疮患者,应更仔细地监测这些合并症的存在。